Document:

EX-10.14

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

Exhibit 10.14 

DEVELOPMENT AND CLINICAL MANUFACTURE AGREEMENT 

This Development and Clinical Manufacture Agreement (the “Agreement”) is made and entered into as of June 5, 2012 (the
“Effective Date”) by and between Metabolex, Inc., a Delaware corporation with its principal place of business located at 3876 Bay Center Place, Hayward, California 94545 (“Metabolex”) and Patheon Inc.,
a Canadian company with its principal place of business located at 2100 Syntex Court, Mississauga, Ontario, L5N 7K9, Canada (“Patheon”). Metabolex and Patheon may be referred to herein individually as a “Party” or
collectively as the “Parties”.  
 RECITALS 

Metabolex desires Patheon to perform certain manufacturing process development work on its proprietary drug compound known as “MBX-102” (also known
as “arhalofenate”) in accordance with the terms and conditions set forth in this Agreement. This Agreement also allows Patheon to manufacture pharmaceutical products intended for use in clinical trials in accordance with the terms and
conditions set forth in this Agreement. 
 Patheon is willing to perform such development and other specified work under the terms and conditions set forth
in this Agreement. 
 Now therefore, the Parties agree as follows: 
  

	1.	DEFINITIONS 

  

	 	1.1.	“Affiliate” means, with respect to a particular Party, any other corporation or other legal entity that controls, is controlled by or is under common control with such Party. For purposes of this
definition, the term “control” (with correlative meanings for the terms “controlled by” and “under common control with”) means that the applicable entity has more than 50% of the voting rights in the controlled entity.

  

	 	1.2.	“API” means the chemical compound known as MBX-102 or arhalofenate, having the chemical structure as described in Exhibit A of this Agreement. 

 

	 	1.3.	“Applicable Law” means all applicable laws, rules, ordinances, and regulations, including any rules, regulations, guidelines or other requirements of relevant government agencies, that may be in
effect from time to time in the applicable country or jurisdiction, including then-current cGMP as applicable to the Services to be provided under this Agreement. 

 

	 	1.4.	 “Confidential Information” means, with respect to a Party, all Information that such Party delivers or discloses to the other Party
pursuant to, or in connection with, this Agreement, regardless of its source, and whether or not the same is specifically identified as being “confidential”. This Agreement constitutes Confidential Information of both Parties. In addition,
but subject to the limitations set forth in Section 7.2, all Information that (i) is disclosed by Metabolex to Patheon regarding the Services to be provided under this 

	 	
Agreement; (ii) is set forth in the Scope of Work; (iii) is developed or generated by Patheon as a result of performing Services under this Agreement, including the Data and
Deliverables; or (iv) comprises the API or otherwise is directly related to the API, shall be deemed to be Confidential Information of Metabolex. 

  

	 	1.5.	“Controlled” means, with respect to a specific material, item of Information or Intellectual Property right, that the applicable Party owns or has a license to such material, item or right and has the
ability to grant the other Party access and a license thereto as provided for in this Agreement without violating or conflicting with any agreement with or rights of a third party. 

 

	 	1.6.	“Current Good Manufacturing Practice” or “cGMP” means the then-current standards for the manufacture of fine chemicals, active pharmaceutical ingredients, intermediates, bulk products
or finished pharmaceutical products set forth (i) in 21 U.S.C. 351(a)(2)(B), in U.S. FDA regulations at 21 C.F.R. Parts 210 and 211 and in The Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice
for Medicinal Products, each as may be amended from time to time; (ii) in International Conference on Harmonization (ICH) Guidelines relating to the manufacture of active pharmaceutical ingredients and finished pharmaceuticals as may be amended
from time to time; (iii) all other similar Applicable Laws relating to the manufacturing of active pharmaceutical ingredients intended for use in humans and promulgated by any other governmental authority having jurisdiction over the
manufacture of drug compounds in the countries in which the Product containing API will be used or sold as communicated to Patheon in writing by Metabolex from time to time and as may be agreed to by Patheon, which agreement shall not be
unreasonably withheld or delayed; and (iv) all additional regulatory authority documents or regulations that replace, amend, modify, supplant or complement any of the foregoing. 

 

	 	1.7.	“Data” has the meaning set forth in Section 6.2. 

  

	 	1.8.	“Deliverable” or “Deliverables” means all deliverables that Patheon agrees to provide to Metabolex under a Plan, and the items set forth in Section 6.1. 

 

	 	1.9.	“FDA” means the United States Food and Drug Administration, or any successor thereto having the administrative authority to regulate the development and marketing of human pharmaceutical products in the
United States. 

  

	 	1.10.	“Information” means any and all information of any kind, including results, data, discoveries, improvements, processes, methods, protocols, formulas, techniques, inventions, know-how and trade secrets,
scientific, chemical, pharmaceutical, toxicological, biochemical, and biological, data, and information relating to the results of tests, assays, methods, processes, and specifications, and/or other documents containing information and related data,
and any assay control, regulatory, and any other test results or information, regulatory, manufacturing, financial, pricing and commercial information or data. 

  

	 	1.11.	“Intellectual Property” or “IP” means all intellectual property, regardless or form and as conferred or established by the laws of any jurisdiction, including published and unpublished works
of authorship; inventions and discoveries (including compositions of matter, methods, processes and improvements thereof); words, names, symbols and designs used to distinguish a business, product, or service; and all Confidential Information.

  
 [*] = Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 2 

	 	1.12.	“Metabolex Materials” means the API, chemical compounds, and other materials specified in each SOW to be supplied by or on behalf of Metabolex to Patheon that are necessary to perform the Services.

  

	 	1.13.	“Quality Agreement” means the Quality Agreement to be entered into by the Parties as described in Section 2.5. 

 

	 	1.14.	“Statement of Work” or “SOW” has the meaning set forth in Section 2.3. 

  

	 	1.15.	“Services” means process development, manufacturing and other services to be performed by Patheon under one or more Statements of Work. 

 

	 	1.16.	“Specifications” means the characteristics, processing requirements, standards and other specifications set forth in the applicable SOW (Exhibit B,) of this Agreement, as may be
amended or supplemented from time to time by mutual agreement of the Parties. 

  

	2.	PURPOSE; SCOPE; PROCESS DEVELOPMENT AND MANUFACTURE 

  

	 	2.1.	Purpose and Intent. The Parties agree that Patheon may, pursuant to the terms of this Agreement, perform product development services for Metabolex including but not limited to drug substance characterization,
pharmaceutical development, process development, analytical method and specification development, and manufacturing of experimental batches and cGMP clinical trial materials using the API or Metabolex Materials as set forth in one or more SOWs.

  

	 	2.2.	Process Development and other Manufacturing Services. Patheon shall perform the process development and/or other manufacturing Services and tasks and activities as set forth in the agreed upon SOW, the form of
which is attached hereto as Exhibit B, as such SOW may be amended from time to time by the written agreement of the Parties. Such Services shall include the preparation and delivery to Metabolex of the Deliverables as set forth in the
SOW. If the Parties agree that Patheon will, under an SOW, manufacture products for Metabolex, Patheon shall manufacture and supply to Metabolex the specified products in such quantities as ordered by Metabolex in orders submitted to Patheon from
time to time by Metabolex in accordance with the Quality Agreement and the applicable SOW, which may be amended from time to time by the written agreement of the Parties. 

 

	 	2.3.	Additional Projects. If Metabolex desires that Patheon perform certain additional activities or tasks relating to process development or manufacturing of API that are outside the scope of the SOW, Metabolex shall
submit a written request to Patheon setting forth in reasonable detail the particular activities or tasks requested for such proposed additional SOW. The Parties shall then negotiate reasonably and in good faith and seek to agree on a written
Statement of Work setting forth such additional activities and tasks, and the specific terms for such proposed SOW (which activities and tasks shall, upon agreement by the Parties to such SOW, be deemed additional Services to be performed
hereunder). Each such SOW shall include a specific description of the particular Services to be performed and the budget, costs and timeline therefore, and all Deliverables to be prepared and delivered to Metabolex, and, as necessary, any additional
Information and requirements for such Services. Each SOW be attached to this Agreement as an exhibit and shall be deemed incorporated herein. Each 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 3 

	 	
agreed SOW may be modified or amended from time to time upon mutual written agreement of the Parties, and such agreed-upon modifications or amendments shall be attached and deemed incorporated
into the applicable SOW. It is contemplated that there may be multiple Statements of Work that shall be sequentially numbered, each referencing and covering a different project. 

 

	 	2.4.	Conflicting Terms. The Parties agree that if there is any conflict between a particular term of a SOW and the terms of this Agreement, the terms of this Agreement shall control and supersede such conflicting term
of the applicable SOW, unless such SOW specifically and expressly provides that such term shall prevail notwithstanding such conflict. 

  

	 	2.5.	Quality Agreement. Prior to Patheon commencing work for Metabolex under a SOW, Patheon and Metabolex shall enter into a quality agreement governing the quality systems used in connection with Patheon’s
performance (the “Quality Agreement”). 

  

	 	2.6.	Schedule and Performance. Patheon will schedule the performance of each of the SOWs (including all Services under the SOW and delivery of all Deliverables) as specified in the SOW applicable to the SOW and will
coordinate with Metabolex as appropriate to ensure the timely commencement and performance of all such Services. Patheon shall perform all the Services and other work under a SOW in accordance with the terms of the applicable SOW, Applicable Law,
and the terms and conditions of this Agreement. Patheon shall perform all the Services and other work under this Agreement using good faith, reasonable care and in accordance with industry practice. Patheon shall provide the facilities and supplies
(other than Metabolex Materials, and subject to the fees set forth in Article 3) and staff necessary to complete all the Services in accordance with the terms of this Agreement and the applicable SOW. All such staff shall have all training,
education and experience needed to perform the applicable Services in a competent and efficient manner. Notwithstanding anything in this Article, the Parties acknowledge and agree that the SOWs may need to be adjusted and adapted depending on the
progress and interim results of the activities performed by Patheon under this Agreement. The Parties further acknowledge that Patheon shall be compensated based on the works done under this Agreement, rather than based on achievement of specific
results. 

  

	 	2.7.	Metabolex Materials. In the preparation or processing of APIs, Patheon agrees to use only those Metabolex Materials that are supplied by Metabolex or obtained by Patheon from a qualified vendor. Patheon shall
determine the amounts of Metabolex Materials that Patheon will need to perform the Services requested by Metabolex. Any Metabolex Materials supplied by or on behalf of Metabolex to Patheon shall only be used for Services associated with Metabolex
SOWs, unless otherwise agreed. All Metabolex Materials shall remain the property of Metabolex at all times. Patheon shall store all Metabolex Materials in appropriate and secure conditions, and shall take all necessary care to prevent damage, loss
or theft of Metabolex Materials. Provider shall clearly identify all Metabolex Materials in storage as goods belonging to Metabolex, and the Metabolex Materials shall be separated from, and not intermingled with, other products although Metabolex
Materials may be stored in the same storage room as other products. At all times, Metabolex Materials shall be stored within the temperature range specified in writing by Metabolex prior to shipment of such materials to Patheon’s facility, and
in each case in accordance with Applicable Law. Patheon shall not transfer or otherwise provide access to the Metabolex Materials to any person or entity other 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 4 

	 	
than its employees or permitted subcontractors without the prior written consent of Metabolex. Patheon shall use the Metabolex Materials solely to perform Services in accordance with this
Agreement and the applicable SOW. Patheon understands and agrees that the Metabolex Materials may have unpredictable and unknown biological and/or chemical properties and are to be used with caution. Patheon will use and handle all Metabolex
Materials in accordance with Metabolex’s written instructions and in compliance with Applicable Law, including, but not limited to, any laws or regulations relating to the testing, storage, transportation, packaging, labeling or other use of
the Metabolex Materials. Metabolex shall be responsible for qualification of vendors of Metabolex Materials and for providing a certificate of compliance confirming that the Metabolex Materials are compliant with the provisions outlined in the
“Note for Guidance on minimizing the risk of transmitting spongiform encephalopathy agents via human and veterinary medicinal products” (EMEA/410/01, Rev.2 or update). Upon the completion or termination of a SOW, Patheon shall either
return or destroy any Metabolex Materials for such SOW that remain in Patheon’s possession in accordance with Metabolex’s written instructions and at Metabolex’s expense. In the event that any quantity of Metabolex Materials provided
to Patheon is lost, or damaged, stolen, destroyed, or otherwise rendered unusable for its intended purpose (e.g., because it was not stored in accordance with the storage conditions specified by Metabolex in writing and in accordance with Applicable
Law) while in Patheon’s custody or control (other than destruction of Metabolex Materials requested or approved by Metabolex), [*], subject to [*]. Nothing in this Agreement shall obligate Patheon to [*] to perform Services under a signed SOW,
and then [*] to perform such Services. 

  

	 	2.8.	Affiliates. Patheon may arrange for any of its Affiliates to perform specific Services under a SOW, and such Affiliate and the Services to be performed shall be specified in that SOW and approved by the Parties.
Each Affiliate performing Services will execute the SOW, which will bind such Affiliate to the terms and conditions contained herein. Patheon shall remain primarily liable for the performance of its Affiliates under any such SOW and its
Affiliates’ compliance with the provisions of this Agreement. 

  

	 	2.9.	Subcontractors. Except as provided in Section 2.9, Patheon may not subcontract any of the Services or other work to be performed by it hereunder without Metabolex’s prior written consent. In the event
that Metabolex does so consent, then any agreement entered into by Patheon with the permitted subcontractor shall, at a minimum, provide for ownership and allocation of Intellectual Property rights and for obligations of confidentiality of
Information, record-keeping, access, rights to data, and performance in accordance with Applicable Law that are consistent with the intent and terms of this Agreement and the Quality Agreement. Patheon shall remain liable for the performance of any
of its obligations hereunder that it delegates to a subcontractor. 

  

	 	2.10.	Shipping. Shipments of Metabolex Materials and manufactured products by Patheon will be made [*], unless otherwise mutually agreed. The Metabolex Materials and manufactured products will be transported in
accordance with the written instructions of Metabolex. Patheon shall package all manufactured products being shipped to Metabolex or other locations designed by Metabolex into secondary packaging for shipment in accordance with instructions provided
by Metabolex. All shipments from Metabolex to Patheon will be made [*], unless otherwise agreed. All shipments of API will be accompanied by certificate(s) of analysis from the API manufacturer including confirmatory results demonstrating that the
API complies with the manufacturer’s API specifications. 

  
 [*] =
Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 5 

	 	2.11.	Changes to a SOW. If Metabolex requests any changes to the scope of a SOW, Patheon will promptly prepare a written change order reflecting such changes, including an estimate of any resulting adjustment to the
timeline for the performance of the Services under the SOW and to the compensation schedule (whether an increase or decrease). Upon Metabolex’s written approval of the change order, such change order shall constitute an amendment to the
applicable SOW and shall be incorporated herein, and Patheon shall perform the Services in accordance with such amended SOW. Notwithstanding anything herein to the contrary, to the extent that any changes to the Services requested by Metabolex
consist of a reduction in the scope of the Services to be performed for a particular SOW, Patheon shall immediately implement such reduction at Metabolex’s request, and the parties shall negotiate in good faith a change order that reduces the
compensation schedule and reflects such change as soon as practicable. 

  

	3.	PAYMENTS 

  

	 	3.1.	Price. 

  

	 	3.1.1.	The price for the Services performed by Patheon shall be in accordance with the pricing schedule set forth in the applicable SOW. Unless otherwise agreed to between the Parties, Patheon will purchase common
materials and supplies required to perform the Services, other than Metabolex Materials. A fixed “[*] Fee” equaling [*], will be included in the project budget to cover [*]. 

 

	 	3.1.2.	The costs of all third party suppliers’ fees and the purchase of project specific items (such as exclusive raw materials, excipients, packaging, special equipment, tooling, change parts, laboratory columns
and reagents, reference standards including those under the applicable United States Pharmacopoeia, the National Formulary, the British Pharmacopoeia, the European Pharmacopoeia or the Japanese Pharmacopoeia) necessary for Patheon to perform the
Services will be purchased by Patheon and charged back to Metabolex [*]. Upon the termination or completion of a SOW, Patheon shall transfer to Metabolex, at Metabolex’s expense, all project specific items in Patheon’s possession that were
charged back to Metabolex. 

  

	 	3.1.3.	If Patheon is required to buy any third party marketed product in order to complete the Services, Metabolex acknowledges that such purchases will be made on behalf of Metabolex [*]. 

 

	 	3.2.	Invoices; Payment. Patheon shall provide to Metabolex an invoice upon completion of the Services relating to a particular SOW, according to the payment schedule set forth in such SOW which invoice shall set forth
the price for such Services in accordance with the applicable SOW and be accompanied by sufficient back-up documentation, if any, necessary to support the payments being invoiced. Metabolex shall pay each undisputed invoice no later than [*] days
following the date of invoice. Patheon shall mail a copy of the invoice to the mailing address provided in Section 16.1, with a copy to be sent by email on the date of invoice to the email address provided in Section 16.1, or to such other
mailing or email address as Metabolex may indicate in writing, from time to time. 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 6 

	 	3.3.	[*] (if Applicable as per the Budget Summary). Metabolex will pay to Patheon any applicable [*] set out in the SOW within [*] days of the date of receipt of invoice for [*]. Patheon will not [*]. The [*]
Services are fully completed [*]. [*]. Patheon [*] Services performed under the applicable SOW that are [*]. Patheon may[*]. 

  

	 	3.4.	Disputed Portions of Invoices. If any portion of an invoice is disputed, then Metabolex will pay Patheon the undisputed amount and the parties will use good faith efforts to reconcile the disputed amount as soon
as practicable. [*]. 

  

	 	3.5.	Acceptance of Deliverables and Services. Metabolex shall have the right to review and test all Deliverables and Services delivered or provided by Patheon under a SOW to confirm that such deliverables comply with
the specifications of the SOW and the obligations of this Agreement. Metabolex may reject any such Deliverables or Services (or portion thereof) if the same do not comply as stated above, or if they are otherwise defective or unsatisfactory, by
providing to Patheon a written rejection within [*] business days from its discovery of such problem, which rejection identifies the basis for such rejection. Metabolex shall not have the obligation to pay for any Deliverable or Service properly
rejected. Within [*] business days of any notice of rejection, Patheon shall present a corrective plan of action to Metabolex. Upon approval by Metabolex of the corrective plan, Patheon, at no additional expense to Metabolex (other than paying for
any additional API or Metabolex Material needed, as set forth in Section 12.5), shall then make the corrections and, where applicable, Patheon shall resubmit the corrected Deliverable or Service to Metabolex. If Metabolex does not reject in
writing within [*] business days of its discovery of a defect or other problem with Deliverables or Services, [*]. 

  

	 	3.6.	Payment Upon Termination by Metabolex. Upon termination of this Agreement or any SOW by Metabolex pursuant to Section 4.2, Metabolex shall pay Patheon full payment for that portion of Services satisfactorily
performed up through the date of termination, [*]. 

  

	4.	TERM, TERMINATION AND RENEWAL  

  

	 	4.1.	Term. This Agreement begins on the Effective Date and expires [*] years from the Effective Date unless earlier terminated pursuant to this Article 4. In the event this Agreement is terminated prior to completion
of a SOW, this Agreement will remain in effect with regard to each ongoing SOW until such SOW is terminated. Each SOW shall be effective upon the effective date specified therein and shall terminate upon (i) the completion of the Services to be
provided thereunder, and (ii) Patheon’s receipt of all fees, and any other payments due to Patheon related to the Services provided thereunder, unless earlier terminated in accordance with this Article 4. 

 

	 	4.2.	Termination by Metabolex. Metabolex may terminate this Agreement or any SOW for any reason upon [*]days written notice to Patheon. 

 

	 	4.3.	[*] Termination or Postponement. If Metabolex terminates this Agreement or any SOW under Section 4.2, or postpones scheduled and reserved manufacturing services pursuant to a SOW[*] of the start date of such
scheduled and reserved manufacturing services (the “Start Date”), 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 7 

	 	
then [*]. If Metabolex terminates this Agreement or any SOW under Section 4.2, or postpones scheduled and reserved manufacturing services pursuant to a SOW [*], then [*]% of the costs of
such scheduled and reserved manufacturing services]. If Metabolex terminates this Agreement or any SOW under Section 4.2, or postpones scheduled and reserved manufacturing services pursuant to a SOW [*], then [*] of the costs of such scheduled
and reserved manufacturing services]. In any such event of termination or postponement by Metabolex, Patheon will use reasonable commercial efforts to utilize its manufacturing facilities for an alternative project[*]. 

 

	 	4.4.	Termination for Material Breach. Each Party may terminate this Agreement or any SOW and all Services then in progress upon written notice if the other Party materially breaches this Agreement and such breaching
Party fails to cure the breach within [*] days after receipt of written notice from the non-breaching Party specifying in detail the nature of such breach. During such [*]day cure period, each Party will continue to perform its obligations under the
Agreement and any applicable SOW. In the event of termination by Metabolex for material breach by Patheon pursuant to Section 4.4, Metabolex shall be obligated to pay Patheon only for Services satisfactorily completed by the effective date of
termination. 

  

	 	4.5.	Return of API; Storage. Upon termination of this Agreement or a SOW, or otherwise upon the request of Metabolex, Patheon shall return any unused Metabolex Materials and related items within [*] days of the date
of such termination or request and all work-in-process and manufactured API, at the expense of Metabolex. Excluding retained samples or stability samples, and unless otherwise agreed between the Parties, Metabolex will [*] after their release for
shipment by Patheon or anticipated use for the Services as the case may be (unless such anticipated use is postponed by Patheon): (i) $[*] all materials and supplies stored at the Patheon’s site under room temperature conditions;
(ii) $[*] for all materials and supplies stored at the Patheon site under conditions of 2 °C - 8 °C; (iii) $[*] for all materials and supplies stored at the Patheon site under conditions of -70 °C; and (iv) If Metabolex
requests storage at conditions different than those stated above (Sec. 4.5(i)-(iii)), then the arrangement and cost will be discussed and agreed between the Parties on a separate basis. Patheon reserves the right to refuse to store any API, products
or other Metabolex property, at its sole discretion, at any time. [*] all risk or loss of damage to the stored Metabolex Materials, products or other Metabolex property stored by Patheon following the [*] of (i) [*] this Agreement; or
(ii) [*] particular Services under the SOW to which such API, products or Metabolex Materials relate; other than [*], and it will be [*] in place for this risk. Patheon will reimburse Metabolex for [*]. 

 

	5.	OWNERSHIP 

  

	 	5.1.	Disclosure of Inventions. Patheon shall notify Metabolex in writing of any and all inventions, technology, discoveries, or ideas, whether patentable or not, conceived, reduced to practice, made, or developed by
Patheon or its agents in the performance of Services or related to the Metabolex Materials or Metabolex Confidential Information (collectively, “Inventions”), promptly after each such conception, reduction to practice, making, or
developing. All inventions, technology, discoveries, or ideas, whether patentable or not, conceived, reduced to practice, made, or developed by Patheon or its agents which have been independently developed without the use or benefit of Metabolex
Materials or Metabolex Confidential Information and which have general application to manufacturing processes or formulation 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 8 

	 	
development of drug products or drug delivery systems will be the exclusive property of Patheon and shall not constitute “Inventions,” as defined in this Section 5.1. Patheon
hereby grants to Metabolex, a non-exclusive, worldwide, paid-up, royalty-free, sublicensable, transferable license of Patheon’s intellectual property that was used by Patheon, its Affiliates or subcontractors for the manufacture of
Metabolex’s products hereunder, solely to make, have made, use, import, offer for sale, or sell such Metabolex products, products incorporating such Metabolex products, and products that have the same API as such Metabolex products.

  

	 	5.2.	Ownership of Inventions. Patheon agrees and acknowledges that Metabolex owns all right, title, and interest in and to all Inventions, and all intellectual property rights arising therefrom. Patheon hereby assigns
and transfers to Metabolex all of its right, title and interest in and to the Inventions (and all intellectual property rights arising therefrom) and agrees to take all further acts reasonably required to evidence such assignment and transfer to
Metabolex at Metabolex’s expense. Patheon shall enter into an agreement with each employee or agent of Patheon performing work in connection with the Services, pursuant to which such person shall grant all rights in the Inventions (and all
intellectual property rights arising therefrom) to Patheon such that Patheon may assign and transfer such rights to Metabolex in accordance with this Section 5.2. Patheon hereby appoints Metabolex as its attorney-in-fact to sign such documents
as Metabolex deems necessary for Metabolex to obtain ownership and to apply for, secure, and maintain patent or other proprietary protection of the Inventions (and all intellectual property rights arising therefrom) if Metabolex is unable, after
reasonable inquiry, to obtain Patheon’s (or its employee’s or agent’s) signature on such a document. All Inventions and any information with respect thereto or intellectually property rights arising therefrom are Metabolex
Confidential Information subject to the confidentiality provisions of Section 7.3. 

  

	 	5.3.	Deliverables. Metabolex owns all right, title, and interest in and to all Deliverables, and all reports and biological or chemical specimens generated by Patheon as a direct result of conducting the Services. All
Deliverables and any information with respect thereto are Metabolex Confidential Information subject to the confidentiality provisions of Section 7.3. 

  

	 	5.4.	Metabolex Property. All tangible property provided to Patheon in connection with this Agreement, including without limitation all Metabolex Materials, records, or other Metabolex Confidential Information (as
defined in Section 7.1), is the exclusive property of Metabolex. 

  

	 	5.5.	Limited License. Metabolex hereby grants to Patheon for the term of this Agreement a nonexclusive, royalty-free, limited (to the scope as described herein) license (without any rights to sublicense) under such
intellectual property, know-how or information that is controlled by Metabolex and is necessary to enable Patheon to perform the Services hereunder solely for the purpose of the performance of Services in accordance with the applicable SOW. Patheon
shall not acquire any other right, title or interest in or to any intellectual property owned or controlled by Metabolex as a result of this Agreement or Patheon’s performance hereunder. 

 

	6.	DELIVERABLES AND RECORDS 

  

	 	6.1.	Deliverables. Patheon agrees to provide to Metabolex (i) all data, certificates of analysis, reports, and other information generated by Patheon in the performance of the Services; (ii) all batches of
API or product containing API that Patheon processes or manufactures under this Agreement; (iii) a detailed description of the processes used to make each batch of API or of 

 
 [*] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 9 

	 	
product containing API (each batch of API or product containing API will be identified by an internal Patheon lot number, with a cross-reference to the identification number for process and
Metabolex Materials utilized in the synthesis), including Patheon’s batch record; and (iv) for each batch shipped, a quality statement certifying whether or not the batch was processed according to cGMPs (Certificate of Compliance) and a
Certificate of Analysis that confirms the API or other product meets the applicable Specifications. Patheon shall also conduct all quality testing provided for in the SOW and the Quality Agreement and provide to Metabolex all documentation of such
quality testing required by the Quality Agreement and/or the applicable SOW. Metabolex has responsibility for API release. Patheon shall deliver to Metabolex various samples of or containing API according to any schedule set forth in a SOW or as
otherwise mutually agreed upon in writing by the Parties. 

  

	 	6.2.	Books and Records. Patheon shall keep complete and accurate books and records related to all Services performed under the Agreement, including covering the manufacture, processing and supply of the API. Patheon
shall also maintain complete, accurate, and authentic documentation, notes, data, test results, records, master batch records, and working batch records for each batch of API, for all Services, and for all other work relating to API and/or any of
the Services generated by Patheon during the performance of, and in connection with, the SOW(s) (collectively, the “Data”). Patheon shall retain such records for a period of [*] years following the date of manufacture or for such
longer period as may be required by the Quality Agreement, the applicable SOW or Applicable Law. Such records shall be made available to Metabolex for inspection, copying and/or audit verification by Metabolex or its designee at any reasonable time
during Patheon regular business hours. Upon Metabolex’s request, Patheon shall make copies of such records available to Metabolex, at Metabolex’s expense. 

 

	7.	CONFIDENTIALITY. 

  

	 	7.1.	Metabolex Confidential Information. Subject to the limitations set forth in Section 7.2, all information that: (i) is disclosed by Metabolex to Patheon regarding the Services; (ii) is disclosed by
Metabolex to Patheon to obtain a price quotation regarding the Services; (iii) is set forth in a SOW; (iv) is developed or generated by Patheon as a result of performing the Services, including the Data and Inventions; or (v) is
related to the Metabolex Materials, including information that relates to the Metabolex Materials and was disclosed by Metabolex to Patheon pursuant to the Confidentiality Agreement entered into by the Parties on March 2, 2012 (the
“Confidentiality Agreement”), shall be deemed to be “Metabolex Confidential Information.” Metabolex Confidential Information may include, without limitation, trade secrets, ideas, patent applications, data,
processes, formulae, programs, compounds, know-how, improvements, designs, information regarding plans for research development, business plans, and budgets, whether disclosed in oral, written, graphic, or electronic form. 

 

	 	7.2.	Exceptions to Confidential Information. Patheon shall not have any obligations under this Agreement with respect to a specific portion of the Metabolex Confidential Information if Patheon can demonstrate by
providing competent tangible proof that such Metabolex Confidential Information: (a) is in the public domain or comes into the public domain through no fault of Patheon; (b) is furnished to Patheon without any restrictions on its
disclosure by a third party rightfully in possession of such information and not subject to a duty of confidentiality with respect to such information; or (c) solely with respect to Metabolex 

 
 [*] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 10 

	 	
Confidential Information provided by Metabolex to Patheon, is already known by Patheon at the time of receiving such Metabolex Confidential Information from Metabolex, as evidenced by
Patheon’s prior written records. For clarity, it is understood that notwithstanding the fact that individual components of information are in the public domain, but a particular compilation or integration of such components is not in the public
domain, the fact that such individual components are in the public domain does not relieve Patheon of its obligations of confidentiality under this Article 7 with regard to the compilation or integration of such components. 

 

	 	7.3.	Non-Disclosure and Non-Use of Confidential Information. During the term of this Agreement and for a period of [*] years after the expiration or termination of this Agreement, Patheon shall maintain all Metabolex
Confidential Information in strict trust and confidence and shall not disclose any such Metabolex Confidential Information to any third party other than Patheon’s or its Affiliates’ employees, consultants or advisors having a need to know
such Confidential Information, or use any such Metabolex Confidential Information received except as may be authorized by the Metabolex’s prior written consent. Patheon may use or disclose Metabolex’s Confidential Information only to the
extent required to perform the Services, and for no other purpose. Patheon shall not file any patent application containing any disclosure or claim, the subject matter of which is derived from the Metabolex Confidential Information. Patheon shall
not use Metabolex Confidential Information for any purpose or in any manner that would constitute a violation of any laws or regulations of the United States. Nothing in this Agreement grants Patheon the right to retain, distribute, or commercialize
any of the Metabolex Confidential Information. Patheon shall procure from each of its employees and subcontractors performing Services hereunder a signed confidentiality agreement containing terms at least as restrictive as those found herein, and
Patheon shall be liable to Metabolex for the breach by any of them of the provisions of this Section 7.3. 

  

	 	7.4.	Third Party Confidential Information. Patheon shall not disclose to Metabolex any confidential or proprietary information that belongs to any third party unless Patheon first obtains the consent of such third
party and enters into a separate confidentiality agreement with Metabolex covering that disclosure. Patheon shall not represent to Metabolex as being unrestricted any designs, plans, models, samples, or other writings or products that Patheon knows
are covered by valid patent, copyright, or other form of intellectual property protection belonging to a third party. 

  

	 	7.5.	Required Disclosures. Notwithstanding any other provision of this Agreement, Patheon may disclose specific Confidential Information to the extent that such disclosure: (i) is in response to a valid order of
a court or other governmental body having jurisdiction or (ii) is otherwise required by applicable law or regulation, provided in either case that Patheon uses best efforts to limit the scope of the disclosure to that which is required,
provides Metabolex with prior written notice of such requirement as soon as reasonably possible, and cooperates with Metabolex in seeking a protective order, confidential treatment, or similar remedy limiting the use and disclosure of any
Confidential Information required to be disclosed. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 11 

	8.	Regulatory Filing and Inspections. 

  

	 	8.1.	Regulatory Inspections. Patheon shall promptly notify Metabolex of any regulatory inspections relating to the Services by any government agency or other regulatory entity including, without limitation, the United
States Food and Drug Administration (the “FDA”), of which it becomes aware. Metabolex shall have the primary responsibility for preparing any responses relating to the Metabolex Materials that may be required by the government
agency or regulatory entity, and Patheon shall have the primary responsibility for preparing any responses relating to the method of performing the Services and Patheon’s operations and procedures. Patheon shall take all reasonable actions
requested by Metabolex to cure deficiencies as noted during any such inspection. 

  

	 	8.2.	Site Visits by Metabolex. Metabolex’s representatives may visit Patheon’s facilities at reasonable times and upon reasonable notice during normal business hours to observe the performance of the
Services. Patheon will assist Metabolex in scheduling such visits. 

  

	 	8.3.	Regulatory Filing. Metabolex will have the sole responsibility for filing of all documents with the applicable regulatory authority (such as the FDA, the Health Products and Food Branch of Health Canada or the
European Medicines Agency) and to take any other actions that may be required for the receipt of approval from the regulatory authority for the commercial manufacture of Metabolex’s products. Where information or data generated by Patheon in
relation to the Services are to be incorporated into documents to be filed by Metabolex with any regulatory authority and such filing may create the possibility of an inspection or audit of Patheon’s facility, then Metabolex shall provide
Patheon with a draft of the applicable portions of such documents incorporating such data so as to give Patheon the opportunity to verify the accuracy and validity of such documents. Metabolex needs to supply only one form of such information or
data when substantially similar documents are being submitted to multiple regulatory authorities. 

  

	9.	FACILITY AND COMPOUND REQUIREMENTS 

  

	 	9.1.	Facility 

  

	 	9.1.1.	All manufacturing Services shall be performed by Patheon solely at the facilities identified in the applicable SOW. In performing the Services, Patheon shall comply with all Applicable Laws for a drug
establishment and obtain and maintain all necessary registrations, licenses and permits. Metabolex shall have the right to review, from time to time as it requests, during normal business hours, and upon written notice of no less than two weeks, all
registrations, licenses and permits of Patheon that are directly related to Patheon’s obligations under this Agreement, including but not limited to those required by the FDA or any other regulatory agency having jurisdiction over Patheon.

  

	 	9.1.2.	For Services under an SOW, Patheon shall ensure that the facility meets all the requirements of a drug establishment promulgated by the FDA at all times during the manufacture of the drug product, and Patheon
shall comply with all aspects required by the Quality Agreement. 

  
 [*]
= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 12 

	 	9.2.	Authority and API Requirements 

  

	 	9.2.1.	Metabolex and Patheon hereby agree that with respect to the Services and the API, and in addition to the other rights and obligations of this Agreement they each have the following responsibilities and
liabilities: 

  

	 	9.2.1.1.	Metabolex shall use good faith reasonable efforts to [*] relating to API manufactured or processed hereunder will provide [*] under this Agreement as required by Applicable Law and will comply with all
regulations for governmental applications, submissions, and approvals. Metabolex further represents, warrants and covenants that no API will be released for human public use or consumption until all requisite governmental approvals thereof have been
obtained for such use and consumption. 

  

	 	9.2.1.2.	Patheon will make its own identification tests on the Metabolex Materials delivered to Patheon before commencing manufacturing or processing of the API and shall not commence manufacturing or processing and shall
notify Metabolex if such tests indicate the Metabolex Materials do not comply with the applicable specifications. 

  

	 	9.2.1.3.	Patheon shall be responsible for manufacturing, processing, storing, handling, and shipping the API in accordance with the specifications provided to Patheon and the agreed upon terms in the relevant SOW.

  

	 	9.2.1.4.	Metabolex and Patheon shall comply with all Applicable Law, rules, regulations, codes, and standards of all federal, state, local and municipal government agencies that affect their respective performance and
activities under this Agreement. Each Party shall provide upon request such information as the other Party reasonably requires for compliance with all Applicable Law, rules, regulations, codes, and standards of all federal, state, local and
municipal government agencies that affect their respective performance and activities under this Agreement. 

  

	10.	REPRESENTATIONS AND WARRANTIES 

  

	 	10.1.	No Inconsistent Obligations or Constraints upon Patheon. Patheon represents and warrants that it is qualified and permitted to enter into this Agreement and that the terms of the Agreement are not in conflict
with its other contractual arrangements. 

  

	 	10.2.	Due Authorization. Each Party represents and warrants that (a) it has the full power and authority to enter into this Agreement, (b) this Agreement has been duly authorized, and (c) this Agreement
is binding upon it. 

  

	 	10.3.	No Debarred Person. Patheon represents and warrants that it shall not employ, contract with, or retain any person or entity directly or indirectly to perform the Services under this Agreement [*] under
investigation by the FDA for debarment or being presently debarred by the FDA pursuant to the Generic Drug Enforcement Act of 1992, as amended (21 U.S.C. § 301, et seq.). In addition, Patheon represents and warrants that, to its best
knowledge, it has not engaged in any conduct or activity that could lead to any such debarment actions. If during the term of this Agreement, Patheon or any person or entity employed or retained by it to perform any Services is debarred[*] then in
each case Patheon shall immediately notify Metabolex of same. 

  
 [*] =
Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 13 

	 	10.4.	No Pending Regulatory Actions. Patheon represents and warrants that as of the Effective Date it is not currently subject to an FDA consent decree or other regulatory action impacting Patheon’s manufacture of
pharmaceutical products under this Agreement. Patheon shall notify Metabolex within [*] business days if Patheon receives any Form 483s or warnings from, or comes under a consent decree issued by, a regulatory authority relating to manufacturing,
supply and distribution services it has provided or related to the facility where it is performing Services hereunder, and will provide to Metabolex copies of all relevant documents relating thereto, except that Patheon shall be permitted to redact
from the copies provided to Metabolex any information contained in such documents that is another Patheon customer’s confidential information. 

  

	 	10.5.	No Infringement. Patheon represents and warrants that the use of methods, processes and software selected by Patheon to perform the Services including, without limitation, Patheon’s IP, in the course of
conducting the Services, will not infringe or misappropriate any intellectual property right of any third party. Metabolex represents and warrants that none of the Metabolex Materials, or Metabolex Intellectual Property, know-how or information that
is provided or disclosed to Patheon for conducting the Services will, if used to conduct Services in accordance with the applicable SOW, infringe or misappropriate any intellectual property right of any third party when used as permitted in this
Agreement. 

  

	 	10.6.	No Pending Litigation. As of the Effective Date, Patheon is not involved in any litigation relating to Patheon’s performance of pharmaceutical development services including, without limitation, clinical
manufacturing services, for any third party. Patheon shall have no obligation to notify Metabolex of any litigation commenced at any time following the Effective Date.” 

 

	 	10.7.	Manufacturing Warranty. Patheon represents and warrants that all products manufactured by Patheon under an SOW shall be manufactured in compliance with the Quality Agreement and all other Applicable Laws and, if
the products are required to be manufactured in accordance with cGMP pursuant to the applicable SOW, such products shall be manufactured in compliance with cGMP and the applicable Specifications. 

 

	11.	INSURANCE. Patheon shall secure and maintain in full force and effect throughout the performance of the Services insurance coverage for (a) employer’s liability, and (b) general liability, in
amounts appropriate to the conduct of Patheon’s business. Certificates evidencing such insurance will be made available for examination upon request by Metabolex. Patheon further agrees to maintain workers’ compensation insurance in the
amount required by the laws of the state in which Patheon’s employees performing the Services are located. 

  

	12.	INDEMNIFICATION AND LIMITATION OF LIABILITY 

  

	 	12.1.	Indemnification by Metabolex. Metabolex shall indemnify, defend, and hold harmless Patheon and Patheon’s directors, officers, employees, and agents (the “Patheon Indemnitees”) from and
against any and all third party liabilities, claims, suits, losses, expenses (including reasonable attorneys’ fees and legal expenses), and costs (collectively “Claims”) resulting from or arising out of (a) the negligence,
gross negligence or intentional misconduct of any of the Metabolex Indemnitees relating to this Agreement or the Services, (b) a breach of Metabolex’s 

 
 [*] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 14 

	 	
obligations, covenants, representations or warranties under this Agreement, or (c) any claim of infringement or alleged infringement of any third party’s intellectual property rights in
the Metabolex Materials or Metabolex IP that Metabolex requires Patheon to use in the performance of Services, in each case to the extent that such infringement or alleged infringement arises out of the use of the Metabolex Materials or Metabolex IP
solely for the purpose of and in accordance with the applicable SOW. Such indemnity shall not apply if Patheon fails to comply with the indemnification procedures set forth in Section 12.3, or to the extent that a Claim arises out of or results
from (i) the negligence, gross negligence or intentional misconduct on the part of any of the Patheon Indemnitees or Patheon’s subcontractors, (ii) a failure of any of the Patheon Indemnitees or Patheon’s subcontractors to comply
with Applicable Law, or (iii) a breach of Patheon’s obligations, covenants, representations, or warranties under this Agreement. 

  

	 	12.2.	Indemnification by Patheon. Patheon shall indemnify, defend, and hold harmless Metabolex and Metabolex’s directors, officers, employees, and agents (the “Metabolex Indemnitees”) from and
against any and all third party Claims resulting from or arising out of (a) the performance of the Services by Patheon; (b) the negligence, gross negligence, or intentional misconduct on the part of the Patheon Indemnitees or
Patheon’s subcontractors relating to this Agreement or the Services, or (c) a breach of Patheon’s obligations, covenants, representations, or warranties under this Agreement. Such indemnity shall not apply if Metabolex fails to comply
with the indemnification procedures set forth in Section 12.3 or to the extent that a Claim arises out of or results from (i) the negligence, gross negligence or intentional misconduct of any of the Metabolex Indemnitees, or (ii) a
breach of Metabolex’s obligations, covenants, representations or warranties under this Agreement. 

  

	 	12.3.	General Conditions of Indemnification. Each Party’s agreement to indemnify, defend and hold the other Party harmless is conditioned on the indemnified Party (i) providing written notice to the
indemnifying Party of any claim for which it is seeking indemnification hereunder promptly after the indemnified Party has knowledge of such claim; (ii) permitting the indemnifying Party to assume full responsibility to investigate, prepare
for, defend against and settle any such claim or demand; (iii) assisting the indemnifying Party, at the indemnifying Party’s reasonable expense, in the investigation of, preparation for and defense of any such claim or demand; and
(iv) not compromising or settling such claim or demand without the indemnifying Party’s written consent. 

  

	 	12.4.	Separate Defense of Claims. In the event that the Parties cannot agree as to the application of Sections 12.1 and 12.2 above to any particular claim, the Parties may conduct separate defenses of such claim. So
long as the Party seeking indemnification has complied with the notice provisions of Section 12.3(i) above and the consent provisions of Section 12.3(iv) above, such Party shall have the right to seek indemnity from the other in accordance
with Section 12.1 or 12.2 (as applicable) above upon resolution of the underlying claim, notwithstanding such Party’s failure to comply with the provisions of Section 12.3(ii) above permitting the indemnifying Party to assume full
responsibility to defend against such claim. 

  

	 	12.5.	Limitations of Liability. If, except for acts of negligence, gross negligence or intentional misconduct, Patheon fails to materially perform any part of the Services in accordance with the terms of this Agreement
or the SOW, then Patheon shall, at Metabolex’s request, either (i)

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 15 

	 	
repeat that part of the Service at Patheon’s costs except that Metabolex will supply the API or Metabolex Materials at Metabolex’s expense; or (ii) reimburse Metabolex for the
price for that part of the Service, excluding the cost of the API or Metabolex Materials. [*] API or Metabolex Materials [*] arises out of [*]. If Patheon fails to materially perform any part of the Services in accordance with the terms of this
Agreement or the SOW because of [*], then in addition to the remedies listed in the first sentence of Section 12.5 above, Patheon will reimburse Metabolex for [*]. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL,
INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION IS INTENDED TO LIMIT OR RESTRICT
THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 12.1 OR 12.2, OR DAMAGES AVAILABLE FOR BREACHES OF THE PROPERTY OWNERSHIP/PATENT RIGHTS IN ARTICLE 5 OR THE CONFIDENTIALITY OBLIGATIONS IN ARTICLE 7. 

 

	13.	SURVIVAL 

 The termination of this Agreement shall not affect the provisions of Articles 1, 5, 7, 9, 10,
12, 14 or Section 16.2, which shall expressly survive any termination. 
  

	14.	PRESS RELEASE 

 No Party shall (i) issue a press release or make any other public statement that
references this Agreement, or (ii) use the other Party’s or its Affiliates’ name or trademarks for publicity or advertising purposes, except, in each case, with the prior written consent of the other Party. For the avoidance of doubt,
Patheon shall not disclose, present, disseminate or produce any publication that contains information regarding the Services, Deliverables or any Confidential Information without Metabolex’s prior written consent. Notwithstanding the foregoing
sentences, either Party may use the name of the other Party in regulatory filings, including filings with the FDA and the United States Securities and Exchange Commission, or in disclosures to investors, partners, potential investors, and potential
partners. For the avoidance of doubt, each Party shall fully comply with Section 7 when issuing a press release or making any other public statement. 
  

	15.	EFFECT OF OTHER AGREEMENTS 

 This Agreement, together with validly approved SOWs, sets forth the
entire agreement between Patheon and Metabolex as to their subject matter and supersedes all other agreements and understandings between the Parties with respect to the same except that the Master Services Agreement titled “Formulation
Development for MBX-102 Tablet (100 mg),” Proposal #MTB-FQ-0001-0401-R2, 30-July-01, and the corresponding Quality Agreement with a signature of last date of 11 March 2011 remain in effect and continue to set forth the entire agreement
between Patheon and Metabolex with respect to the Change of Scope titled “Arhalofenate (MBX 102) IR Tablets – 200 mg,” COS Reference # MTB-FQ-0001-0401-R2-COS-36-R1, dated May 8, 2012.  

 

	16.	MISCELLANEOUS 

  

	 	16.1.	Notices. All notices, consents and approvals required or permitted hereunder shall be given in writing to the other Party by personal delivery, by certified or registered mail, return receipt 

 
 [*] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 16 

	 	
requested, by overnight courier, or by facsimile transmission with electronic confirmation of transmission, at the address specified below or to such other addresses as may be designated in
writing from time to time in accordance with this Section 16.1: 

  

			
	If to Metabolex:	  	Metabolex, Inc.
		  	3876 Bay Center Place
		  	Hayward, CA 94545
		  	Attention: Legal Department
		  	Fax [*]
		  	Email address for invoices: Violet Yung, [*]
		
	For Patheon:	  	Patheon Inc.
		  	2100 Syntex Court
		  	Mississauga, Ontario L5N 7K9
		  	Attention: Legal Department
		  	Fax [*]

  

	 	16.2.	Governing Law. Any claim, dispute, or controversy of whatever nature arising out of or relating to this Agreement shall be governed by and construed in accordance with the laws of the State of New York, without
giving effect to any choice of law principles that would require the application of the laws of a different state. 

  

	 	16.3.	Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. 

 

	 	16.4.	Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original. Copies of original signature pages sent by facsimile and/or PDF shall have the
same effect as signature pages containing original signatures. 

  

	 	16.5.	Amendment, Waiver. This Agreement may be amended, modified, superseded or canceled, and any of the terms may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party
or Parties waiving compliance. The delay or failure of any Party at any time or times to require performance of any provisions shall in no manner affect the rights at a later time to enforce the same. No waiver by any Party of any condition or of
the breach of any term contained in this agreement in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement.

  

	 	16.6.	No third party Beneficiaries. No third party, including any employee of any Party to this Agreement, shall have or acquire any rights by reason of this Agreement. 

 

	 	16.7.	Assignment. Neither this Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned, in whole or in part, by Patheon without the prior written consent of Metabolex, which
consent may not be unreasonably withheld, provided however, that Patheon may, without such consent but upon prior written notice to Metabolex, assign its rights and obligations under this Agreement in connection with a merger, consolidation or sale
of substantially all of the business to which this Agreement relates, to an unrelated third party. However, if Patheon assigns this Agreement to an unrelated third party in connection with a 

 
 [*] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 17 

	 	
merger, consolidation or sale of substantially all of the business to which this Agreement relates and all Services under all SOWs have not been completed as of the effective date of such
assignment, Metabolex shall have the right to terminate this Agreement and any such SOWs effective upon written notice to Patheon, without having to pay any termination or cancellation penalties set forth in Section 4.3 in connection with such
termination. Patheon may arrange for any of its Affiliates to perform specific Services under a SOW. Each Affiliate performing Services will execute the SOW which will bind such Affiliate to the terms and conditions contained herein. Patheon shall
remain primarily liable for the performance of its Affiliates under any such SOW. Any attempted assignment of this Agreement not in compliance with this Section 16.7 shall be null and void. This Agreement shall inure to the benefit of and be
binding upon each Party signatory hereto, its successors and permitted assigns. No assignment shall relieve either Party of the performance of any accrued obligation that such party may then have under this Agreement. 

 

	 	16.8.	Force Majeure. Neither Metabolex nor Patheon shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such
failure or delay is due to natural disasters or any causes reasonably beyond the control of Metabolex or Patheon, as applicable. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical and
shall take reasonable, diligent efforts to remove the condition constituting force majeure or to avoid its effects so as to resume performance as soon as practicable. 

 

	 	16.9.	Severability. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the Parties that the remainder
of the Agreement shall not be affected. The Parties shall make a good faith effort to replace any such provision with a valid and enforceable one such that the objectives contemplated by the parties when entering this Agreement may be realized.

  

	 	16.10.	Relationship of Parties. The relationship between the Parties is that of independent contractors. Neither Party, nor any employee or agent of such Party, shall have the authority to bind or act on behalf of the
other Party without its prior written consent. No employee or agent of Patheon shall be considered to be an employee or agent of Metabolex, and no employee or agent of Metabolex shall be considered to be an employee or agent of Patheon. Each Party
shall be solely and entirely responsible for its acts and for the acts of its employees and agents during performance of this Agreement. This Agreement shall not constitute, create, or in any way be interpreted as a joint venture, partnership or
business organization of any kind. 

  

	 	16.11.	Construction. Section headings are included in this Agreement merely for convenience of reference; they are not to be considered part of this Agreement or used in the interpretation of this Agreement. No rule of
strict construction will be applied in the interpretation or construction of this Agreement. 

  

	 	16.12.	Foreign Corrupt Practices Act. Patheon agrees that it will perform the Services in compliance with all applicable export or import laws of the United States or any foreign jurisdiction. Further, Patheon and its
personnel, agents and representatives are aware of, and agree to abide by, the obligations imposed by the United States Foreign Corrupt Practices Act with 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 18 

	 	
respect to dealing with payments or gifts to governments or related persons for the purpose of obtaining or retaining business for or with, or directing business to, any person. Accordingly,
Patheon agrees that no portion of monies paid or payable to Patheon in connection with this Agreement, nor any other item of value, shall, directly or indirectly, be paid, received, transferred, loaned, offered, promised or furnished to, or for the
use of, any officer or employee of any government department, agency, instrumentality or corporation thereof, or any political party or any official of such party or candidate for office, or any person acting for or on behalf of any of the
foregoing, for the purpose of obtaining or retaining business for or with, or directing business to, any person. Patheon will comply with the applicable provisions of 42 USC § 1320a-7b prohibiting illegal remuneration (including kickback, bribe
or rebate). 

  

	 	16.13.	EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER METABOLEX NOR PATHEON MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR
IMPLIED WARRANTIES OF MERCHANTABILITY, TITLE, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE. 

 [Remainder of page
intentionally left blank] 
  
 [*] = Certain confidential information contained in
this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 19 

 In witness whereof, the parties hereto have duly executed this Agreement as of the Effective Date. 

 

									
	METABOLEX, INC.	 		 	PATHEON INC.
					
	By:	 	 /s/ Raymond Urbanski
	 		 	By:	 	 /s/ Rita Terzian

			
	 R. Urbanski
	 		 	 Rita Terzian

	Print Name	 		 	Print Name
			
	 CMO
	 		 	 Sr. Director, POS IRO

	Title	 		 	Title

  
 [*] = Certain confidential information contained in this
document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 20 

 Exhibit A 

API 
 [*] 

 
 [*] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 21 

 Exhibit B 

Form of Statement of Work 

Statement of Work No.      

THIS SCOPE OF WORK NO.     (a “Statement of
Work”) is made and entered into as of             , 20    , by and between Metabolex, Inc. a Delaware corporation with a business address of 3876 Bay
Center Place, Hayward, California 94545 (“Metabolex”) and Patheon Inc., a Canadian company with its principal place of business located at 2100 Syntex Court, Mississauga, Ontario, L5N 7K9, Canada (“Patheon”). 

Pursuant to the terms and conditions of the Development and Clinical Manufacture Agreement of         Patheon
has agreed to perform certain services in accordance with written Scopes of Work, such as this one, entered into from time-to-time. 
 The parties hereby
agree as follows: 
 1. Statement of Work. This document constitutes a “Statement of Work” under the Development and
Clinical Manufacture Agreement, and this Statement of Work and the work contemplated herein are subject to the terms and provisions of the Development and Clinical Manufacture Agreement. 

2. Services and Payment of Fees and Expenses. The specific work contemplated by this Statement of Work and the related payment terms
and obligations are set forth on the following attachments, which are incorporated herein by reference: 
  

			
	DESCRIPTION OF WORK	  	ATTACHMENT 1
	PROJECT BUDGET	  	ATTACHMENT 1
	TIMELINE	  	ATTACHMENT 1
	PAYMENT SCHEDULE	  	ATTACHMENT 1

 3. Term. The term of this Statement of Work shall commence on
            , 20    and shall continue until the services described in Attachment 1 are completed, unless this Statement of Work is terminated in accordance with
the Development and Clinical Manufacture Agreement. 
 4. Amendments. No modification, amendment, or waiver of this Statement of Work
shall be effective unless in writing and duly executed and delivered by each Party to the other. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 22 

 Exhibit B, continued 

ACKNOWLEDGED, ACCEPTED AND AGREED TO: 
  

									
	Metabolex, Inc.	 		 	Patheon Inc.
					
	By:	 	  
	 		 	By:	 	  

			
	  
	 		 	  

	Print Name	 		 	Print Name
			
	  
	 		 	  

	Title	 		 	Title

  
 [*] = Certain confidential information contained in this
document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

  
 23EX-10.15

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

Exhibit 10.15 
 METRICS,
INC. 
 STANDARD DEVELOPMENT AGREEMENT 

THIS AGREEMENT, effective as of October 31, 2006, by and between Metrics, Inc., a North Carolina corporation, having a principal place of
business at 1240 Sugg Parkway, Greenville, NC 27834 (“METRICS”), and Metabolex, Inc., a Delaware corporation, having a principal place of business at 3876 Bay Center Place, Hayward, CA 94545 (“COMPANY”). 

WITNESSETH 
 WHEREAS,
COMPANY is engaged in the business of the research, development and commercialization of pharmaceutical and biotechnology products; 

WHEREAS, METRICS is engaged in the business of, among other things, providing contract pharmaceutical development, formulation and analytical
services; 
 WHEREAS, COMPANY desires to engage the services of METRICS to assist COMPANY in certain pharmaceutical development activities
upon the terms and conditions set forth herein; 
 WHEREAS, METRICS performance pursuant to this Agreement may require the use by METRICS of
COMPANY owned intellectual property that is necessary or useful to the development services provided hereunder; and WHEREAS, METRICS performance pursuant to this Agreement may require the parties to disclose to each other confidential and
proprietary information, inventions, trade secrets and know-how, which must be protected from disclosure to third parties; 
 NOW,
THEREFORE, in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto do hereby agree as follows: 

 

	 	1.	Definitions. 

  

	 	1.1	Applicable Law means all applicable federal, state, and local laws, ordinances, and regulations applicable to the Services, including without limitation GLP. 

 

	 	1.2	 Confidential Information means any and all information furnished by the disclosing party to the receiving party that is designated as
confidential or that would ordinarily be considered confidential, including but not limited to, the chemical structure of any drug 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	
substance or active pharmaceutical ingredient (“API”) provided to METRICS, the formulation and/or optimization of any drug substance and/or API into capsules and/or tablets, the
development plans and strategies of COMPANY as to any product candidate, information set forth in the Work Statement, information related to the Materials and/or any other information developed or generated by METRICS as a result of performing the
Services (including the Inventions), procedures, manufacturing techniques, analytical methods and techniques, testing methods, developments, results, data, study results (including analytical testing and stability results, and including the Study
Data), conclusions, technologies, inventions, development plans, business or financial information, and any of METRICS’ price estimates, proposals, quotations, or similar pricing information. 

 

	 	1.3	Deliverables means all data (including the Study Data), results, products, substances and materials to be developed for or delivered to COMPANY by METRICS as provided in this Agreement and under any Work
Statement issued hereunder. 

  

	 	1.4	GLP means the Good Laboratory Practices promulgated from time to time by the United States Food and Drug Administration. 

  

	 	1.5	Initial Work Statement means the initial Work Statement between the parties attached hereto as Schedule A. 

  

	 	1.6	Invention means any intellectual property, whether patentable or not, know-how, trade-secret, discovery, technology, process, procedure, manufacturing technique, analytical method and technique, innovation,
invention, improvement and the like developed in the course and scope of this Agreement. 

  

	 	1.7	COMPANY Invention means an Invention made or conceived solely by COMPANY’s employees in the course and scope of this Agreement. 

 

	 	1.8	METRICS Invention means an Invention made or conceived solely by METRICS’ employees in the course and scope of this Agreement. 

  

	 	1.9	Joint Invention means an Invention jointly made or conceived by COMPANY’s employees and METRICS’ employees in the course and scope of this Agreement. 

 

	 	1.10	Licensed Intellectual Property means all COMPANY owned patents, patent applications, prospective patents, copyrights, trademarks, trade secrets, technology, Confidential Information and other intellectual
property that are necessary or useful to the Services to be provided by METRICS hereunder. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	1.11	Product means a pharmaceutical product developed or manufactured for COMPANY by METRICS as provided in this Agreement and under any Work Statement issued hereunder. 

 

	 	1.12	Services means the services described in Section 2.1 and the additional services described in Section 2.2. 

  

	 	1.13	Work Statement means a schedule agreed to by the parties that outlines, among other things, the plan for development services to be provided by METRICS, the particular services to be provided by METRICS, any
Deliverables or Products to be developed or manufactured by METRICS, the time schedule for performance, and the amount, schedule and method of payment to be made by COMPANY. Any Work Statement may be modified or amended from time to time upon mutual
written agreement of the parties, and such agreed-upon modifications or amendments shall be attached as part of the appropriate schedule and incorporated herein. 

  

	 	2.	Scope and Purpose. 

  

	 	2.1	Services. METRICS agrees to use commercially reasonable efforts to provide the services outlined in the Initial Work Statement set forth in Schedule A attached hereto. 

 

	 	2.2	Additional Services. METRICS agrees to provide additional services specified in any future Work Statements that may be agreed to between the parties in writing, incorporated into this Agreement and attached
hereto as additional schedules. Each Work Statement shall be governed by the terms and conditions of this Agreement and by such supplementary written amendments of this Agreement as may be, from time to time, executed between the parties. In the
event of a conflict between the terms and conditions of this Agreement and any Work Statement, the terms of this Agreement shall govern. 

  

	 	2.3	Performance of Services. METRICS shall perform the Services using reasonable care, in accordance with the Work Statement, Applicable Law, COMPANY’s instructions, and the terms and conditions of this
Agreement. METRICS shall use its best efforts to provide the facilities, supplies (other than the materials that will be provided by COMPANY) and staff necessary to complete the Services in accordance with the terms of this Agreement. METRICS shall
conduct and complete the Services in accordance with the time schedule set forth in the Work Statement, subject to any delays caused by COMPANY’s failure to timely provide to METRICS Materials or any other items needed by METRICS from COMPANY
to commence or complete the Services. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	2.4	Change Orders. COMPANY may, from time to time, submit to METRICS a request for changes to an existing Work Statement. If, in METRICS’ reasonable judgment, METRICS can implement the requested changes without
requiring additional METRICS’ time or resources and without affecting METRICS’ ability to maintain the project schedule, METRICS will implement the change at no additional cost to COMPANY. Otherwise, METRICS will provide COMPANY with a
written change order proposal for the additional work, including: (i) price change, (ii) impact on project schedule, and (iii) revised Work Statement, including additional requirements of COMPANY, if any. COMPANY may, at its
discretion, accept or reject METRICS’ change order proposal. COMPANY shall be deemed to have accepted METRICS change order proposal if [*] business days pass without COMPANY providing its written acceptance, rejection or proposed modification
of such proposal. Each party will use reasonable efforts to respond as expeditiously as possible to change order proposals. 

  

	 	2.5	Materials and Information to be Provided. COMPANY agrees to provide METRICS with all relevant information, documentation materials, candidate techniques for development, samples, specimens and the like
(“Materials”), that are necessary for METRICS’ performance under this Agreement. COMPANY and/or its agents and/or subcontractors shall provide METRICS with sufficient amounts of the Materials necessary to perform the Services. METRICS
shall use the Materials solely for the purpose of performing the Services. METRICS shall not supply the Materials, or any portion thereof, to any third parties other than a subcontractor approved by COMPANY to perform work in connection with this
Agreement. METRICS will use the Materials in compliance with all Applicable Laws and regulations, including, but not limited to, any laws or regulations relating to the testing, storage, transportation, packaging, labeling, or other authorized use
of the Materials. METRICS shall retain the unused portion of any Materials until such time as COMPANY requests that such Materials be returned or destroyed. 

  

	 	2.6	 Study Data. All data and other information generated or recorded in the performance of the Services, including any summary information based
thereon, shall be referred to herein as the “Study Data.” METRICS shall create and maintain written records of the Study Data and other information related to the performance of the Services in a timely, accurate, complete, and legible
manner in the form as agreed between the parties. METRICS shall maintain the 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	
Study Data in compliance with the terms and conditions of this Agreement, the Work Statement, and Applicable Law. METRICS shall maintain the Study Data in a professional manner so as to permit
COMPANY to review the Study Data in full without disclosing to COMPANY any third party confidential or proprietary information in any review that COMPANY may perform hereunder. METRICS shall make the Study Data available for COMPANY’s
inspection and copying during regular business hours and upon reasonable advance notice, provided that COMPANY or its representative may not audit, copy or inspect such records more than once per calendar year. Promptly upon completion or
termination of the Services, METRICS shall transfer to COMPANY all Study Data or, at COMPANY’s request, shall maintain the Study Data. METRICS shall not destroy any Study Data until the earlier of (a) [*] or (b) its receipt of
COMPANY’s prior written permission to do so. METRICS may in any event retain one true copy of all Study Data, which it may use solely to comply with its obligations under Applicable Law and this Agreement. 

 

	 	2.7	Reports of Results. Upon completion of the Services, or at other time points as the parties may agree, METRICS shall provide written reports of Study Data, in both electronic and hard copy format to COMPANY and,
at COMPANY’s request, to such other third parties as directed by COMPANY. All reports provided to COMPANY by METRICS shall be deemed COMPANY Confidential Information subject to the obligations of confidentiality set forth in Section 5.

  

	 	2.8	Subcontractors. METRICS may utilize subcontractors with appropriate expertise and experience in the performance of its obligations under this Agreement; provided, however, that COMPANY must give its written
approval, which shall not be unreasonably withheld, prior to the use of subcontractors by METRICS. METRICS shall ensure that all subcontractors employed by METRICS in connection with the Services shall execute such instruments as are necessary to
confirm such subcontractor’s obligations in connection with this Agreement. METRICS shall remain liable for the performance of any of its obligations hereunder that it delegates to a subcontractor. 

 

	 	2.9	Work Location. METRICS shall perform the Services at the location indicated in the applicable Work Statement, or, if no such location is indicated, at the address given above for METRICS unless mutual agreement
to the contrary has been made and stipulated by the parties. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	3.	Compensation. In return for the performance by METRICS of, and as compensation for, the Services, COMPANY agrees to pay METRICS the amounts specified in the Initial Work Statement in the attached Schedule A and
any future Work Statements that may be agreed to by the parties. COMPANY understands and agrees that METRICS reserves the right to revise the charge estimates in a Work Statement should the scope of METRICS’ services change or should unforeseen
difficulties arise; provided, however, that the parties must mutually agree to any such change. Unless otherwise agreed, METRICS will invoice COMPANY on the schedule set forth in the Work Statement or if not set forth in the Work Statement after
completion of the Services, with payment due within [*] days of the receipt of an invoice. The invoice shall explicitly refer to the Services performed so as to allow COMPANY to cross-check the completed Services against the Work Statement and
schedule of payments. The invoice shall also be accompanied by reasonable back-up documentation, if applicable. 

  

	 	4.	Shipping. Deliverables to be delivered by METRICS under this Agreement shall be shipped by METRICS to COMPANY or locations designated by COMPANY as directed by COMPANY. METRICS shall be responsible for arranging
all shipping, as appropriate, including suitable packaging materials to comply with applicable standards, customs forms and insurance. Risk of loss shall transfer to COMPANY upon placement of the Deliverables in the hands of a carrier mutually
acceptable to the parties. METRICS shall invoice COMPANY for shipping, insurance and any sales, use, excise, import, customs or similar taxes as outlined in the Work Statement. 

 

	 	5.	Confidentiality. 

  

	 	5.1	Confidential Information. During the term of this Agreement and for a period of [*] years after the expiration or termination of this Agreement, Confidential Information shall be held in confidence and shall not
be used by the receiving party for any purpose other than to fulfill its obligations under this Agreement and shall not be disclosed to any third party (except as otherwise required or permitted by this Agreement); provided, however, that the
receiving party may disclose such information: (i) on a need-to-know basis to its agents, employees and consultants who are under a written obligation to maintain the confidentiality of such Confidential Information on terms substantially
similar to those set forth in this Agreement and (ii) to investigators retained in connection with a study to which such Confidential Information relates, and who are under a written obligation to maintain the confidentiality of such
Confidential Information on terms substantially similar to those set forth in this Agreement. In each such case the receiving party shall be responsible to the disclosing party for breaches by any person to whom the receiving party discloses
Confidential Information. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	5.2	Use. Neither party shall file any patent application containing any disclosure or claim, the subject matter of which is derived from the Confidential Information of the other party. Neither party shall use the
Confidential Information of the other party for any purpose or in any manner that would constitute a violation of any laws or regulations of the United States. Except as otherwise provided herein, neither party shall have the right to retain,
distribute, or commercialize any of the Confidential Information of the other party. 

  

	 	5.3	Limitation. The receiving party shall have no obligations of confidentiality with respect to any portion of Confidential Information that: (i) is or later becomes generally available to the public by use,
publication or the like, through no fault of the receiving party; (ii) is obtained without restriction from a third party who had the legal right to disclose the same to the receiving party; (iii) the receiving party already possesses, as
evidenced by its written records, predating receipt thereof from the disclosing party; or (iv) is required to be disclosed by order of a governmental authority or a court of competent jurisdiction; provided that the receiving party shall,
whenever reasonably possible, give the disclosing party notice of such requirement and an opportunity to be heard on the issue prior to disclosing the Confidential Information. 

 

	 	5.4	Third Party Confidential Information. METRICS shall not disclose to COMPANY any confidential or proprietary information that belongs to any third party unless METRICS first obtains the consent of such third party
and enters into a separate confidentiality agreement with COMPANY covering that disclosure. METRICS shall not represent to COMPANY as being unrestricted any designs, plans, models, samples, or other writings or products that METRICS knows are
covered by valid patent, copyright, or other form of intellectual property protection belonging to a third party. 

  

	 	5.5	Return of Information. Any and all written information or other materials in tangible or electronic form received by the receiving party from the disclosing party and all copies, notes, and other materials made
by the receiving party regarding Confidential Information shall upon termination of this Agreement, or earlier at the disclosing party’s request, be immediately destroyed or, at the disclosing party’s option, returned. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	6.	Inspections. 

  

	 	6.1	Regulatory Inspections. METRICS shall promptly notify COMPANY of any regulatory inspections relating to the Services by any government agency or other regulatory entity including, without limitation, the United
States Food and Drug Administration (the “FDA”), of which it becomes aware. COMPANY shall have the primary responsibility for preparing any responses relating to the Materials that may be required by the government agency or regulatory
entity, provided, however, that if any such FDA inspection takes place at METRICS’ facility, [*], though [*]. METRICS shall [*] preparing any responses relating to [*]. METRICS shall take all reasonable actions to cure deficiencies as noted
during any such inspection. 

  

	 	6.2	Site Visits by COMPANY. COMPANY’S representatives may visit METRICS’ facilities at reasonable times and upon reasonable notice during normal business hours to observe the performance of the Services.
METRICS will assist COMPANY in scheduling such visits. The site visits described in this Section 6.2 shall be [*], and COMPANY [*]. 

  

	 	7.	COMPANY License Grant. COMPANY hereby grants to METRICS a limited, non-exclusive right and license to use Licensed Intellectual Property solely for the purpose of enabling METRICS to carry out its tasks and
responsibilities under this Agreement and under any Work Statement issued hereunder. 

  

	 	8.	Ownership and Rights. 

  

	 	8.1	Intellectual Property Rights Related to a Product. Any and all intellectual property rights related to a Product, or API provided to METRICS, including but not limited to, patents and patent applications [*] such
Product or API, shall be the sole and exclusive property of COMPANY. COMPANY shall be responsible for the preparation, filing and prosecution of patent or other intellectual property applications relating to such Product or API at its own expense
(unless otherwise agreed by both parties) and its own discretion. METRICS shall assist COMPANY, at COMPANY’s expense, with the preparation of all documents necessary to effectuate COMPANY’s rights related to such Product or API.

  

	 	8.2	 COMPANY Inventions. COMPANY shall own all right, title and interest in any COMPANY Inventions; provided, however, that COMPANY shall provide
METRICS a nonexclusive, irrevocable, royalty-free license to the use of any such COMPANY Inventions, for purposes not related to a Product or to API provided to METRICS, that resulted from the use by COMPANY of

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	
Confidential Information disclosed to COMPANY by METRICS. COMPANY shall be responsible for the preparation, filing and prosecution of patent or other intellectual property applications for any
such COMPANY Inventions at its own expense (unless otherwise agreed by both parties) and its own discretion. METRICS shall assist COMPANY, at COMPANY’s expense, with the preparation of all documents necessary to effectuate COMPANY’s rights
in COMPANY Inventions. 

  

	 	8.3	METRICS Inventions. METRICS shall own all right, title and interest in any METRICS Inventions; provided, however, that METRICS shall [*] METRICS Inventions resulting from (i) [*], (ii) [*], or
(iii) [*]. METRICS shall be responsible for the preparation, filing and prosecution of patent or other intellectual property applications for any such METRICS Inventions at its own expense (unless otherwise agreed by both parties) and its own
discretion. COMPANY shall assist METRICS, at METRICS’ expense, with the preparation of all documents necessary to effectuate METRICS’ rights in METRICS Inventions. 

 

	 	8.4	Joint Inventions. COMPANY and METRICS shall own an equal and undivided interest in any Joint Invention that is not related to a Product or to API provided to METRICS. The parties shall confer and mutually
determine which party (or parties) will be responsible for the preparation, filing, and prosecution of any patent or other intellectual property applications pertaining to any Joint Invention that is not related to a Product or to API provided to
METRICS. COMPANY shall own all Joint Inventions that are related to a Product or to API provided to METRICS. COMPANY will be responsible for the preparation, filing, and prosecution of any patent or other intellectual property applications
pertaining to any Joint Inventions that are related to a Product or to API provided to METRICS. 

  

	 	8.5	Further Assurances. Each party shall ensure that it has in place with each of its applicable employees or agents, appropriate arrangements whereby such party will be able to satisfy its obligations under this
Section 8. 

  

	 	8.6	Study Data. COMPANY shall own all right, title, and interest in and to all Study Data, and all reports and biological or chemical specimens generated by METRICS as a result of conducting the Services. All Study
Data and any information with respect thereto shall be COMPANY Confidential Information subject to the confidentiality provisions of Section 5. 

  

	 	8.7	COMPANY Property. All tangible property provided to METRICS in connection with this Agreement, including without limitation all Materials, records, or other COMPANY Confidential Information, shall be and remain
the exclusive property of COMPANY. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	9.	Representations and Warranties. 

  

	 	9.1	COMPANY Representations and Warranties. COMPANY represents and warrants that it has the right to enter into this Agreement, that it is not a party to any existing agreements, grants, licenses, encumbrances,
obligations, or agreements, written or oral, inconsistent with this Agreement, that it [*], and that it [*]. COMPANY further represents and warrants that it has no present knowledge of the existence of United States patents or other intellectual
property rights that would be infringed by the development and manufacture of Products under this Agreement. 

  

	 	9.2	METRICS Representations and Warranties. METRICS represents and warrants that it has the right to enter into this Agreement and that it is not a party to any existing agreements, grants, licenses, encumbrances,
obligations, or agreements, written or oral, inconsistent with this Agreement. METRICS further represents and warrants that it has no present knowledge of the existence of United States patents or other intellectual property rights that would be
infringed by the development and manufacture of Products under this Agreement. 

  

	 	9.3	No Debarred Person. METRICS represents and warrants that it shall not employ, contract with, or retain any person directly or indirectly to perform the Services under this Agreement if such person is under
investigation by the FDA for debarment or is presently debarred by the FDA pursuant to the Generic Drug Enforcement Act of 1992, as amended (21 U.S.C. § 301, et seq.). In addition, METRICS represents and warrants that it has not engaged in any
conduct or activity that could lead to any such debarment actions. If during the term of this Agreement, METRICS or any person employed or retained by it to perform the services (i) comes under investigation by the FDA for a debarment action,
(ii) is debarred, or (iii) engages in any conduct or activity that could lead to debarment, METRICS shall immediately notify COMPANY of same. 

  

	 	9.4	 NO OTHER REPRESENTATIONS. THE EXPRESS REPRESENTATIONS AND WARRANTIES STATED IN THIS SECTION 9 ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND
WARRANTIES, EXPRESS OR 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	
IMPLIED, INCLUDING WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 

 

	 	10.	Insurance. METRICS shall secure and maintain in full force and effect throughout the performance of the services insurance coverage for (a) employer’s liability, (b) general liability, and
(c) professional services indemnity in amounts appropriate to the conduct of METRICS business. Certificates evidencing such insurance will be made available for examination upon request by COMPANY. METRICS and COMPANY each also agree that it
will maintain adequate insurance to cover its indemnification obligations hereunder. METRICS further agrees to maintain workers’ compensation insurance in the amount required by the laws of the state in which METRICS employees performing the
Services are located. 

  

	 	11.	Indemnification. 

  

	 	11.1	Indemnification by COMPANY. COMPANY hereby agrees to defend, indemnify, and hold METRICS and METRICS’ directors, officers, employees, and agents (the “METRICS Indemnitees”) harmless from and
against any and all expenses, losses, royalties, profits, damages, liabilities, settlements, claims or demands, including reasonable attorneys’ fees, to the extent arising from or in connection with any third party claim that: (i) involves
the breach by COMPANY of any of its obligations, warranties or representations under this Agreement; (ii) [*]; (iii) involves the [*]; or (iv) involves the [*]. Such indemnity shall not apply if METRICS fails to comply with the
indemnification procedures set forth in Section 11.3, or to the extent that a claim arises out of or results from (i) the negligence, gross negligence, or intentional misconduct on the part of any of the METRICS Indemnitees, (ii) a
failure of any one of the METRICS Indemnitees to comply with Applicable Law in the performance of the Services, or (iii) a material breach of METRICS’ obligations, covenants, representations, or warranties under this Agreement.

  

	 	11.2	 Indemnification by METRICS. METRICS hereby agrees to defend, indemnify, and hold COMPANY and COMPANY’S directors, officers, employees, and
agents (the “COMPANY Indemnitees”) harmless from and against any and all expenses, losses, royalties, profits, damages, liabilities, settlements, claims or demands, including reasonable attorneys’ fees, to the extent arising from or
in connection with any third party claim that involves: (i) the negligence, gross negligence, or intentional misconduct on the part of any of the METRICS Indemnitees, (ii) a failure of any one of the METRICS Indemnitees to comply with
Applicable Law in 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	
the performance of the Services, or (iii) a breach of METRICS’ obligations, covenants, representations, or warranties under this Agreement. Such indemnity shall not apply if COMPANY
fails to comply with the indemnification procedures set forth in Section 11.3, or to the extent that a claim arises out of or results from (i) the breach by COMPANY of any of its obligations, warranties or representations under this
Agreement; (ii) [*]; (iii) [*]; (iv) [*]; (v) the negligence, gross negligence, or intentional misconduct on the part of any of the COMPANY Indemnitees. 

 

	 	11.3	General Conditions of Indemnification. Each party’s agreement to indemnify, defend and hold the other party harmless is conditioned upon the indemnified party (i) providing written notice to the
indemnifying party of any claim for which it is seeking indemnification hereunder promptly after the indemnified party has knowledge of such claim; (ii) permitting the indemnifying party to assume full responsibility to investigate, prepare for
and defend against any such claim or demand; (iii) assisting the indemnifying party, at the indemnifying party’s reasonable expense, in the investigation of, preparation for and defense of any such claim or demand; and (iv) not
compromising or settling such claim or demand without the indemnifying party’s written consent. 

  

	 	11.4	Separate Defense of Claims. In the event that the parties cannot agree as to the application of Sections 11.1 and 11.2 to any particular claim, the parties may conduct separate defenses of such claim. So long as
the party seeking indemnification has complied with the notice provisions of Section 11.3(i) and the consent provisions of Section 11.3(iv), such party shall have the right to seek indemnity from the other in accordance with
Section 11.1 or 11.2 (as applicable) above upon resolution of the underlying claim, notwithstanding such party’s failure to comply with the provisions of Section 11.3(ii) permitting the indemnifying party to assume full responsibility
to defend against such claim. 

  

	 	12.	Term, Termination and Survival. 

  

	 	12.1	Term. This Agreement shall be effective upon the date specified at the beginning of this Agreement and shall continue until terminated by either party at any time on [*] days prior written notice. Upon
termination, COMPANY shall be obligated to pay the cost of all work completed through the effective date of termination in accordance with the foregoing, as well as [*]. 

 

	 	12.2	Survival. In the event of any termination of this Agreement, Sections 2.6, 2.7, 5, 6, 8, 9.4, 11, 12, and 13 shall survive and shall be binding upon the parties respective successors and assigns.

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	13.	Miscellaneous. 

  

	 	13.1	[*]. COMPANY shall not [*] during the term of this Agreement [*] of [*] pursuant to this Agreement. For the purposes of this Section 13.1, a “[*]” shall be [*] has provided [*] pursuant to this
Agreement within [*], and at the time of [*] pursuant to this Agreement [*]. Notwithstanding the foregoing, [*] shall not include (i) [*], (ii) [*], and (iii) [*]. 

 

	 	13.2	Force Majeure. Either party shall be excused from delays in performing or from its failure to perform hereunder to the extent that such delays or failures result from causes beyond the reasonable control of such
party; provided that, in order to be excused from delay or failure to perform, such party must act diligently to remedy the cause of such delay or failure. 

  

	 	13.3	No Agency. METRICS, in rendering performance under this Agreement, is acting solely as an independent contractor. In no way is METRICS to be construed as the agent or acting as the agent of COMPANY in any
respect, any other provisions of this Agreement notwithstanding. 

  

	 	13.4	Multiple Counterparts/Signatures. This Agreement may be executed in several counterparts, all of which taken together shall constitute one single Agreement between the parties. Facsimile and PDF signatures shall
have the same effect as original signatures. 

  

	 	13.5	Section Headings, Schedules. The section and subsection headings used herein are for reference and convenience only, and shall not enter into the interpretation hereof The schedules referred to herein and
attached hereto, or to be attached hereto are incorporated herein to the same extent as if set forth in full herein. 

  

	 	13.6	Required Approvals. Where agreement, approval, acceptance, or consent by either party is required by any provision of this Agreement, such action shall not be unreasonably delayed or withheld. 

 

	 	13.7	No Waiver. No delay or omission by either party hereto to exercise any right or power occurring upon any noncompliance or default by the other party with respect to any of the terms of this Agreement shall impair
any such right or power or be construed to be a waiver thereof. A waiver by either of the parties hereto of any of the covenants, conditions, or agreements to be performed by the other shall not be construed to be a waiver of any succeeding breach
thereof or of any covenant, condition, or agreement herein contained. Unless stated otherwise, all remedies provided for in this Agreement shall be cumulative and in addition to and not in lieu of any other remedies available to either party at law,
in equity, or otherwise. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	13.8	Authority of METRICS. METRICS has the sole right and obligation to supervise, manage, contract, direct, procure, perform, or cause to be performed all work to be performed by METRICS hereunder unless otherwise
provided herein. 

  

	 	13.9	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. 

  

	 	13.10	Time is of the Essence. For the purposes of this Agreement, including the Initial Work Statement and any other Work Statement, time shall be of the essence. METRICS shall promptly provide written notice to
COMPANY of any change in its ability to provide the Services in accordance with the schedule set forth in the Initial Work Statement or any Work Statement. 

  

	 	13.11	Entire Agreement. This Agreement and the schedules annexed hereto constitute the entire agreement between the parties. No change, waiver, or discharge hereof shall be valid unless it is in writing and is executed
by the party against whom such change, waiver, or discharge is sought to be enforced. 

  

	 	13.12	Notices. All notices required or permitted hereunder shall be given in writing and sent by facsimile transmission, or mailed postage prepaid, certified or registered mail, return receipt requested, or sent by a
nationally recognized express courier service, or hand-delivered at the following addresses (or as subsequently noticed to the other party): 

  

			
	if to METRICS:	  	Metrics, Inc.
		  	1240 Sugg Parkway
		  	Greenville, North Carolina 27834
		  	Facsimile: [*]
		  	Attention: President
		
	if to COMPANY:	  	Metabolex, Inc.
		  	 3876 Bay Center Place
 Hayward, CA
94545

		  	Facsimile: [*]
		  	Attention: General Counsel

 All notices shall be deemed made upon receipt by the addressee as evidenced by a written receipt or three
(3) days after posting if sent by registered U.S. mail. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

	 	13.13	No Assignment. Neither party may, without the prior written consent of the other party, assign or transfer this Agreement or any obligation incurred hereunder, except by merger, reorganization, consolidation, or
sale of all or substantially all of such party’s assets. Any attempt to do so in contravention of this Section shall be void and of no force and effect. This Agreement shall inure to the benefit of and be binding upon each party signatory
hereto, its successors and permitted assigns. 

  

	 	13.14	Use of Names. Neither party shall use the name of the other party or the names of the employees of the other party in any advertising or sales promotional material or in any publication without prior written
permission of such other party; provided, however, that COMPANY may use the name of METRICS in regulatory filings, including filings with the FDA and the United States Securities and Exchange Commission, or in disclosures to investors and potential
partners. 

  

	 	13.15	Severability. If any provision of this Agreement shall be deemed void in whole or in part for any reason whatsoever, the remaining provisions shall remain in full force and effect. The parties shall make a good
faith effort to replace any such provision with a valid and enforceable one such that the objectives contemplated by the parties when entering this Agreement may be realized. 

 

	 	13.16	No Implied Rights or License. No right or license is granted under this Agreement by either party to the other, either expressly or by implication, except as specifically set forth herein. 

IN WITNESS WHEREOF, METRICS and COMPANY have caused this Agreement to be signed and delivered by their duly authorized officers, all as of the
date first hereinabove written. 
  

									
	METRICS	 		 	COMPANY
	Metrics, Inc.	 		 	Metabolex, Inc.
					
	By:	 	 /s/ Jeffery C. Basham
	 		 	By:	 	 /s/ Harold Van Wart

					
	Name:	 	 Jeffery C. Basham
	 		 	Name:	 	 Harold Van Wart

					
	Title:	 	 VP, Marketing & Sales
	 		 	Title:	 	 Chief Executive Officer

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended. 

 SCHEDULE A 

Initial Work Statement 
 [*] 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]